Mural Oncology plc
NasdaqGM MURA
Mural Oncology plc Price to Sales Ratio (P/S) on December 30, 2024: 20.53
Mural Oncology plc Price to Sales Ratio (P/S) is 20.53 on December 30, 2024, a -31.01% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
-
Mural Oncology plc 52-week high Price to Sales Ratio (P/S) is 35.09 on March 07, 2024, which is 70.94% above the current Price to Sales Ratio (P/S).
-
Mural Oncology plc 52-week low Price to Sales Ratio (P/S) is 19.09 on July 05, 2024, which is -7.01% below the current Price to Sales Ratio (P/S).
-
Mural Oncology plc average Price to Sales Ratio (P/S) for the last 52 weeks is 24.26.
Key data
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
Market news
Loading...
NasdaqGM: MURA
| CEO | Ms. Caroline J. Loew Ph.D. |
| IPO Date | Nov. 16, 2023 |
| Location | Ireland |
| Headquarters | 10 Earlsfort Terrace |
| Employees | 107 |
| Sector | Health Care |
| Industries | |
Description
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email